Your browser doesn't support javascript.
loading
Kohlschütter-Tönz syndrome: Case report with novel feature and detailed review of features associated with ROGDI variants.
Liepina, Lelde; Kalnina, Marija Luize; Micule, Ieva; Gailite, Linda; Rots, Dmitrijs; Kalnina, Julija; Strautmanis, Jurgis; Celmina, Marta.
Afiliação
  • Liepina L; Department of Neurology and Neurosurgery, Children's Clinical University Hospital, Riga, Latvia.
  • Kalnina ML; Department of Neurology and Neurosurgery, Children's Clinical University Hospital, Riga, Latvia.
  • Micule I; Faculty of Residency, Riga Stradins University, Riga, Latvia.
  • Gailite L; Department of Clinical Medical Genetics and Prenatal Diagnostics, Children's Clinical University Hospital, Riga, Latvia.
  • Rots D; Scientific Laboratory of Molecular Genetics, Riga Stradins University, Riga, Latvia.
  • Kalnina J; Scientific Laboratory of Molecular Genetics, Riga Stradins University, Riga, Latvia.
  • Strautmanis J; Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Celmina M; Department of Conservative Dentistry and Oral Health, Institute of Stomatology, Riga Stradins University, Riga, Latvia.
Am J Med Genet A ; 188(4): 1263-1279, 2022 04.
Article em En | MEDLINE | ID: mdl-34939736
ABSTRACT
Kohlschütter-Tönz syndrome (KTS) is a rare, autosomal recessive syndrome characterized by a triad of epilepsy, amelogenesis imperfecta and severe global developmental delay. It was first described in a Swiss family in 1974 by Alfried Kohlschütter and Otmar Tönz. It is caused by pathogenic variants in the ROGDI gene. To the best of our knowledge, there are currently 43 patients with a confirmed ROGDI gene pathogenic variant reported. Here, we review in detail the clinical manifestations of KTS, provide an overview of all reported genetically confirmed patients, and document an additional case of KTS-a 6-year-old Latvian girl-with a confirmed ROGDI gene pathogenic variant. In contrast to previous reports, we detected idiopathic bilateral nephrocalcinosis in this newly identified KTS patient. Perampanel proved an effective treatment for our patient with prolonged super-refractory status epilepticus. In order to better characterize this rare syndrome and its clinical course, it is important to report any additional symptoms and also the effectiveness of used therapies. Future research should focus on elucidating the mechanisms by which the absence/insufficiency of ROGDI-encoded protein causes the clinical manifestations of KTS. This knowledge could shape possible ways of influencing the disease's natural history with more effective therapies.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Epilepsia / Amelogênese Imperfeita Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Child / Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Epilepsia / Amelogênese Imperfeita Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Child / Female / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article